Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Single Arm Open Label Study of Erlotinib and 13-cis-Retinoic Acid (CRA) in Patients With Recurrent Malignant Gliomas

NCT01103375 is registered in ClinicalTrials.gov with Wake Forest University Health Sciences as lead sponsor.

NCT NCT01103375
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01103375 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Single Arm Open Label Study of Erlotinib and 13-cis-Retinoic Acid (CRA) in Patients With Recurrent Malignant Gliomas
Lead sponsor
Wake Forest University Health Sciences
Phase
Phase 1
Overall status
Terminated
Start date
May 31, 2010
Completion date
March 31, 2013
Enrollment
5 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

adult anaplastic astrocytoma, adult anaplastic oligodendroglioma, adult diffuse astrocytoma, adult giant cell glioblastoma, adult glioblastoma, adult gliosarcoma, adult mixed glioma, adult oligodendroglioma, recurrent adult brain tumor